STEBA
Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
Inclusion Criteria:
-
New or recurrent low-grade, non-invasive UTUC disease
-
Karnofsky Performance Status ≥ 50%
Exclusion Criteria:
-
Current high-grade or muscle invasive (>pT1) urothelial carcinoma of the bladder
-
Carcinoma in situ (CIS) current or previous in the upper urinary tract
-
History of invasive T2 or higher urothelial cancer in past 2 years
Principal Investigator: